What a GLP-1 Membership Fee Actually Buys

Ask what a GLP-1 costs at a telehealth provider and you will usually get one number. Most bills have two lines. The membership is the smaller one at signup, the larger one by month three, and the only one that changes without anyone telling you.

The line that is not the drug

Mochi puts it about as plainly as this category gets. Its product pages carry an asterisk reading "Requires a Mochi Health Membership. Cost of medication not included in Mochi Health Membership Fee," and its homepage footnote repeats the point from the other side: "Medications and diagnostic services not included in membership subscription."¹

Two subscriptions, running in parallel, each with its own price and its own promotional structure. Neither page shows their sum.

The fee that changes while the drug price does not

The membership is where the escalation lives, and operators are usually willing to say so in a footnote.

Mochi: "The $39 promotional rate applies to your first month only for new customers. After that, the standard rate is $79 per month."¹ That is a 103% increase on line one of the bill in month two.

Ro: "$39 to start and as low as $74/mo ongoing on an annual prepaid plan," with the range spelled out in its own risk copy — "After your first month, you'll be charged $74-149/mo depending on the plan you choose."²

In both cases the medication line does not move at the same time. The escalation is entirely on the fee, which is why a bill that looked like a bargain in month one looks like something else in month three. Full arithmetic in our Ro review and Mochi Health review.

What providers say the fee includes

Ro's own description of what the fee buys: it "unlocks access to GLP-1s, licensed providers, and ongoing care."²

Found's is more specific about the boundary: "Every plan includes full access to our licensed medical team, personalized care plans. Some also include prescription medication costs—if the cost of your medication isn't included, we'll note that upfront."³

That second sentence is the useful one. It concedes the thing the category usually leaves ambiguous — that whether the drug is inside the price is a per-plan fact, not a category fact.

The fee that is the entire product

Calibrate does not sell a medication at all. Its pricing page: "Lab tests and prescription medications are not included in the membership cost, but we'll work with your commercial/employer insurance to get them covered. Medication copays with insurance are typically $25/month or less after any deductible is met."⁴

So $199 a month buys clinicians, coaching, curriculum and insurance navigation. Nothing you inject. And the $25 figure is a description of a typical commercially insured member's copay, quoted "after any deductible is met" — not a price Calibrate charges or controls.

This is a legitimate model, and it is priced honestly on the page. It is simply a different product from everything else on this list, and comparing its $199 against another provider's $199 compares a service against a service plus a drug. Our Calibrate review prices the whole path.

The provider that charges no fee at all

Strut Health's compounded oral semaglutide page lists $99 and states: "Price includes physician consultations and free shipping."⁵

One line. Whatever else is true of that product — and it is a compounded medication, with everything that implies for regulation and supply, covered in how compounded GLP-1 pricing actually works — the number on the page is the number on the card. See our Strut Health review.

What the law requires of the fee's terms

A recurring membership charge made online is a negative-option feature, governed by the Restore Online Shoppers' Confidence Act. ROSCA makes it unlawful to charge unless the seller "provides text that clearly and conspicuously discloses all material terms of the transaction before obtaining the consumer's billing information," obtains "express informed consent" before charging the card, and provides "simple mechanisms for a consumer to stop recurring charges."⁶

Read against the footnotes above, that is a low bar and most operators clear it. "Clearly and conspicuously" is not the same as "next to the headline price", and disclosure requires nothing of the escalation's size.

The rule layered on top of ROSCA is in motion: the FTC published a Federal Register notice in February 2026 revising its Negative Option Rule to conform to federal court decisions, and issued an advance notice of proposed rulemaking in March 2026 seeking comment on amendments intended to let consumers cancel "without unwarranted obstacles."⁷ Until that lands, the footnote is the disclosure.

A fair test for whether a fee is worth paying

The fee is not automatically waste. It buys prescriber time, follow-ups, refill management and, in some models, insurance navigation that is genuinely hard to do alone. The question is what it costs annually, against what it replaces.

Three numbers settle it.

The fee's ongoing rate, not its intro rate — the second number in the footnote, not the first.

The annual total of that fee alone. At $79 a month that is $948; at $149 it is $1,788; at $199 it is $2,388.

Whether the drug is inside it. If it is not, add the second line before comparing anything to anything.

Then read how to read a GLP-1 provider's pricing page, which turns those three into six questions you can run against any page in about two minutes.